RE: Potential for Re-Rating10 Jun 2020 09:00
An update on FDA meeting due, they would have had to let the market know if it had been delayed.
An update on the progress of Ureka, also their involvement in the French consortium put together by the French government.
An update on BioAMP-B, which given its safety profile, could be a market leader!